Proteasome inhibition as a novel therapeutic target in human cancer.
about
SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myelomaA Runx1-Smad6 rheostat controls Runx1 activity during embryonic hematopoiesisConcise total synthesis of (+/-)-salinosporamide A, (+/-)-cinnabaramide A, and derivatives via a bis-cyclization process: implications for a biosynthetic pathway?Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementNeuropathic cancer pain: What we are dealing with? How to manage it?Targeting NF-kappaB in Waldenstrom macroglobulinemiaUbiquitination and degradation of the inhibitors of NF-kappaBTargeting NF-kappaB in hematologic malignanciesSelective cytotoxicity of amidinopiperidine based compounds towards Burkitt's lymphoma cells involves proteasome inhibitionTriptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expressionBortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myelomaHuman cancer cells retain modest levels of enzymatically active matriptase only in extracellular milieu following induction of zymogen activationUtilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myelomaCul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesisWhy don't we get more cancer? A proposed role of the microenvironment in restraining cancer progressionRole of the ubiquitin system and tumor viruses in AIDS-related cancer.Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumorsBortezomib (Velcadetrade mark) in the Treatment of Multiple MyelomaClinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.Update on the optimal use of bortezomib in the treatment of multiple myelomaVorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell modelsWedelolactone Acts as Proteasome Inhibitor in Breast Cancer CellsNovel Strategies to Improve the Endocrine Therapy of Breast Cancer.Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradationBiological approaches to therapy of pancreatic cancer.The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cellsp21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis.A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancerInteraction of natural products with cell survival and signaling pathways in the biochemical elucidation of drug targets in cancer.Novel therapeutic targets in myeloma bone disease.Acylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation.Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors.
P2860
Q24306820-8E0BC826-C022-4089-9A46-11C9F4C77039Q24634134-7BDBA066-6685-4C94-9DB4-FA31A74E8C05Q24642621-EB8AEBC4-88AD-490B-ADE4-D31D7DF8F714Q26998884-D8A21430-E9C0-43A9-B4D1-5A2CD7EC456EQ26998945-846477DE-74B2-4D72-B530-9C547591C1E5Q28272373-C2281888-14C1-4B1E-A99E-5E831A8BCB9AQ28274205-369C3FDD-93A4-4CF2-AE3A-997DC2994AEFQ28299055-BE8D6493-10A8-4448-89D6-5499D5BCA5B6Q28481652-80BE949B-A2DE-4A86-8DEC-76F4C366E1B3Q28484018-FFF6AD9E-505F-44C6-A451-4642B0AEBA71Q28534703-AF0B3AED-6779-40C0-888B-26B9340B6EA5Q28541376-3E2C3BCA-BC1B-4150-B8DF-1E5388DF4090Q28544663-072F7F48-5BD6-4545-89A0-F62EFBABFB8AQ28593723-25DC78A5-8DA1-4C13-8D48-5F15E8D5D268Q29614274-40A10A95-CE98-4D63-B85F-1E502D86ABD7Q33307881-4B8B1562-00F8-4423-803F-14F78F0C71D3Q33316357-82B7CCF7-4EAB-4D3D-A5AA-548154497E6DQ33378902-0A8DFCA1-F9A0-4B97-9801-0C0300DF36EAQ33379044-FF61DCF2-9558-4863-A01A-9159C779043DQ33391725-EBEB851D-E24C-4D87-ACB7-CBF08DCF288DQ33394153-3E289C0C-417E-4FCD-A1C0-CC57D87C20C9Q33394873-9E6075A6-1E08-49EC-9743-DAE1B75E4BEFQ33414603-B613B8C7-4911-451F-9718-8983C790DBEAQ33417803-D4568CE6-1F9E-4E46-BA02-E555011599B3Q33418098-505A3768-87D1-4277-A306-5538F6D45507Q33440007-BD660CFC-B729-4F12-BF6C-3A7E3D9CD27EQ33620173-0EC55B7C-8E05-4CB3-A6AE-19BF58658134Q33624386-ABDBACD9-3AC0-4DB1-8827-6ECDD8AEF034Q33727284-68E49E8C-A7D7-42CE-8AE7-556BEAE087CBQ33737084-047F4BAD-0972-4422-87BD-61C51AD0B91DQ33772264-CA889166-251A-4136-A84E-B9F4D211A61EQ33855223-8F8FFBD8-C5D7-4AD2-B626-EA01C6FAFBE2Q33899938-7DFB5ACC-5837-47E8-AA83-CD6BC164DC14Q33905852-BCDF01F0-E673-4E96-9A25-6CE46506A7F5Q33921377-B732C9D5-3DCF-47BB-A5B3-02562BE2DF29Q33946183-5E25DA6C-E249-42F7-8D64-A3F4A006944FQ33985206-80D631F6-8A6E-40A0-9925-F49F50D03A0EQ34025065-704A5951-C5E3-4AF4-AC0E-EB2163BA1E8EQ34053359-12B5365B-0A05-4BBE-BBFE-078E62F478A6Q34119207-F54F3224-04CB-484C-8162-B92A33897351
P2860
Proteasome inhibition as a novel therapeutic target in human cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Proteasome inhibition as a novel therapeutic target in human cancer.
@ast
Proteasome inhibition as a novel therapeutic target in human cancer.
@en
type
label
Proteasome inhibition as a novel therapeutic target in human cancer.
@ast
Proteasome inhibition as a novel therapeutic target in human cancer.
@en
prefLabel
Proteasome inhibition as a novel therapeutic target in human cancer.
@ast
Proteasome inhibition as a novel therapeutic target in human cancer.
@en
P356
P1476
Proteasome inhibition as a novel therapeutic target in human cancer
@en
P2093
Paul G Richardson
Teru Hideshima
P304
P356
10.1200/JCO.2005.11.030
P407
P577
2005-01-01T00:00:00Z